Health and wellness company Fiji Kava has appointed Dr Anthony Noble as its new CEO effective May 31.
Noble is currently the MD and CEO of Australian Biotherapeutics and has experiences in natural product development, sales and operations management.
“Anthony’s experience and background in the natural products and biotechnology industries is directly transferable to Fiji Kava, including operational supply chain excellence and in growing the availability of our Fijian Noble Kava across key international markets with new and existing partners,” said Fiji Kava chairman, Dr Andrew Kelly.
“We were extremely impressed by the success of Australian Biotherapeutics under the leadership of Anthony including the role he played in securing investment and commissioning their $10m greenfield production facility in Queensland.”
Prior to Australian Biotherapeutics, Noble spent 10 years at SFI Health, SFI Research as global head of innovation, and head of North Asia, GM of the company’s Chinese joint venture and global head of business to business.
Nicholas Simms, who has been acting as interim CEO, will continue as a non-executive director with founder Zane Yoshida on the Fiji Kava Board.